Physician profile
Kevin Jackson
NPI 1588977508
$4,741.47
in general payments reported to CMS, 2019-2025
27 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $369 · 2021: $257 · 2022: $708 · 2023: $846 · 2024: $959 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,812 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,812.47 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $741.88 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Mallinckrodt Hospital Products INC. | $657.31 | 2022-2025 | Acthar |
| Oyster Point Pharma, INC. | $632.45 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $349.94 | 2022-2025 | Xiidra, Miebo, Infuse |
| Allergan, INC. | $333.37 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $237.24 | 2019-2023 | |
| Amgen INC. | $190.62 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $185.62 | 2019-2021 | |
| Abbvie INC. | $178.12 | 2022-2025 | |
| Biotissue Holdings INC. | $155.93 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $143.73 | 2024-2025 | Xdemvy |
| Spinal Elements, INC. | $139.76 | 2022 | |
| Aerie Pharmaceuticals, INC. | $106.41 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $96.36 | 2019-2025 | |
| Johnson & Johnson Vision Care, INC. | $81.83 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $73.10 | 2022-2023 | Dextenza |
| Carl Zeiss Meditec, INC. | $65.17 | 2021 | |
| Horizon Therapeutics Plc | $51.93 | 2023 | Tepezza |
| Dompe US, INC. | $51.78 | 2024-2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $50.86 | 2025 | Purified Cortrophin Gel, Iluvien |
| Genentech USA, INC. | $47.96 | 2024-2025 | Vabysmo |
| Eyevance Pharmaceuticals LLC | $47.36 | 2019-2020 | |
| Lkc Technologies, INC. | $45.67 | 2024 | |
| Coopervision INC. | $22.75 | 2022 | |
| Astellas Pharma US INC | $21.77 | 2025 | Izervay |
| Rxsight INC | $18.12 | 2022 | |
| Genzyme Corporation | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.